Omeros (NASDAQ:OMER) Trading Up 9.2% – Should You Buy?

Omeros Co. (NASDAQ:OMER) shares shot up 9.2% during mid-day trading on Wednesday . The stock traded as high as $8.74 and last traded at $8.64. 291,193 shares traded hands during trading, a decline of 47% from the average session volume of 544,800 shares. The stock had previously closed at $7.91.

Wall Street Analysts Forecast Growth

Several brokerages recently commented on OMER. D. Boral Capital reaffirmed a “buy” rating and issued a $36.00 price objective on shares of Omeros in a research report on Tuesday. Needham & Company LLC reiterated a “hold” rating on shares of Omeros in a research note on Tuesday. Finally, StockNews.com raised Omeros from a “sell” rating to a “hold” rating in a research report on Tuesday. Three investment analysts have rated the stock with a hold rating, two have given a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat, Omeros currently has a consensus rating of “Moderate Buy” and a consensus target price of $22.50.

Omeros Stock Performance

The stock has a market capitalization of $409.93 million, a price-to-earnings ratio of -3.06 and a beta of 2.35. The firm’s 50 day moving average is $8.58 and its 200-day moving average is $7.61.

Institutional Investors Weigh In On Omeros

Several institutional investors have recently bought and sold shares of the company. Truvestments Capital LLC increased its position in shares of Omeros by 116.5% during the fourth quarter. Truvestments Capital LLC now owns 3,102 shares of the biopharmaceutical company’s stock worth $31,000 after purchasing an additional 1,669 shares in the last quarter. Tower Research Capital LLC TRC boosted its stake in Omeros by 79.0% during the 4th quarter. Tower Research Capital LLC TRC now owns 4,467 shares of the biopharmaceutical company’s stock worth $44,000 after purchasing an additional 1,972 shares during the last quarter. Quantbot Technologies LP purchased a new stake in shares of Omeros during the fourth quarter worth $46,000. BNP Paribas Financial Markets lifted its stake in shares of Omeros by 130.6% in the third quarter. BNP Paribas Financial Markets now owns 12,388 shares of the biopharmaceutical company’s stock worth $49,000 after buying an additional 7,016 shares in the last quarter. Finally, Picton Mahoney Asset Management boosted its position in Omeros by 692.5% during the fourth quarter. Picton Mahoney Asset Management now owns 5,040 shares of the biopharmaceutical company’s stock worth $50,000 after acquiring an additional 4,404 shares during the last quarter. 48.79% of the stock is currently owned by institutional investors and hedge funds.

About Omeros

Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases, including complement-mediated diseases, cancers, and addictive and compulsive disorders. The company’s products under development include Narsoplimab (OMS721/MASP-2) that has completed pivotal trial for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); that is in Phase III clinical trial for the treatment of immunoglobulin A nephropathy (IgAN); and Phase II clinical trial to treat COVID-19.